AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MESOBLAST LTD

1.880

+0.000

Volume:1.62M

Turnover:3.05M

Market Cap:2.40B

PE:-13.07

High:1.905

Open:1.880

Low:1.855

Close:1.880

Loading ...

Overview Company News Filings

Mesoblast Seeks US FDA Meeting to Discuss Approval for Heart Failure Drug Candidate

MT Newswires Live

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Mesoblast (ASX:MSB) Announces Ryoncil Availability But Sees 15% Price Drop Over Past Week

Simply Wall St.

BRIEF-Mesoblast Says Co Entered Medicaid National Drug Rebate Agreement With US CMS For Ryoncil

Mesoblast Enters Agreement for Ryoncil Treatment Access in US

MT Newswires Live

First Three Children to Commence Treatment With Ryoncil®

Mesoblast Ltd - Entered Into Medicaid National Drug Rebate Agreement With U.S. CMS for Ryoncil

THOMSON REUTERS

Thursday’s HotCopper Trends: Mesoblast bags FDA tick, Hot Chili extends mine life | March 27, 2025

The Market Herald

Why Domain, Mesoblast, Pro Medicus, and Tuas shares are tumbling today

Ryoncil® is Now Available for Purchase in the United States

Mesoblast's Ryoncil Becomes Available for Purchase in US

MT Newswires Live

Here are the top 10 ASX 200 shares today

Mesoblast Lists Pricing for FDA-Approved Inflammatory Disease Treatment

MT Newswires Live

BUZZ-ASX-listed Mesoblast climbs on Ryoncil pricing information release

Investors push Mesoblast (ASX:MSB) 18% lower this week, company's increasing losses might be to blame

Simply Wall St.

Mesoblast Limited (MESO): Among the Best Australian Stocks to Buy According to Billionaires

Mesoblast Added to S&P/ASX 200 INDEX

BUZZ-Mesoblast tumbles as biotech firm starts trading as part of Australian benchmark index

BRIEF-Mesoblast Added To S&P Asx200 Index

Why Appen, Mesoblast, Rio Tinto, and Woodside shares are falling today

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSB.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":1.88,"timestamp":1746152181769,"preClose":1.88,"halted":0,"volume":1620947,"delay":0,"nameEN":"MESOBLAST LTD","floatShares":784338594,"shares":1277239284,"eps":-0.1438729667649595,"marketStatus":"Trading","change":0,"latestTime":"05-02 12:16:26 AEST","open":1.88,"high":1.905,"low":1.855,"amount":3053563,"amplitude":0.026596,"askPrice":1.88,"askSize":23840,"bidPrice":1.875,"bidSize":7261,"shortable":3,"etf":0,"ttmEps":-0.1438729667649595,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746165600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":1.88,"openAndCloseTimeList":[[1746144000000,1746165600000]],"volumeRatio":0.884233,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":784338594,"roa":"-4.85%","roe":"-21.31%","lyrEps":-0.139005,"volumeRatio":0.884233,"shares":1277239284,"dividePrice":0,"high":1.905,"amplitude":0.026596,"preClose":1.88,"low":1.855,"week52Low":0.88,"pbRate":"3.34","psRate":"271.58","week52High":3.37,"institutionHeld":0,"latestPrice":1.88,"committee":-0.53307,"eps":-0.1438729667649595,"divideRate":0,"volume":1620947,"delay":0,"ttmEps":-0.1438729667649595,"open":1.88,"prevYearClose":3.1,"prevWeekClose":1.79,"prevMonthClose":1.795,"prevQuarterClose":1.96,"fiveDayClose":1.79,"twentyDayClose":1.935,"sixtyDayClose":3.19},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524478432","title":"Mesoblast Seeks US FDA Meeting to Discuss Approval for Heart Failure Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2524478432","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524478432?lang=en_us&edition=fundamental","pubTime":"2025-04-03 09:56","pubTimestamp":1743645382,"startTime":"0","endTime":"0","summary":"Mesoblast  requested a Type B meeting with the US Food and Drug Administration to discuss the accelerated approval pathway for its drug candidate, Revascor, in treating ischemic chronic heart failure, according to a Thursday filing with the Australian bourse.The meeting will focus on key aspects of the approval process, including manufacturing, potency assays, and confirmatory trial design, the filing said.The meeting is expected to take place this quarter, the filing added.Shares of the company fell nearly 2% in recent Thursday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7501","MESO","BK7067","BK4139","MSB.AU"],"gpt_icon":0},{"id":"2524942872","title":"Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2524942872","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524942872?lang=en_us&edition=fundamental","pubTime":"2025-04-03 07:15","pubTimestamp":1743635700,"startTime":"0","endTime":"0","summary":"NEW YORK, April 02, 2025  -- Mesoblast , global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Administration  to discuss the accelerated approval pathway for Revascor  in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction  and inflammation.In a Type B meeting last year, FDA provided guidance to Mesoblast that the company was eligible to file for accelerated approval of REVASCOR in patients with end-stage HFrEF based on the totality of data across two randomized controlled trials. FDA also guided that a single confirmatory trial in class II/III patients with ischemic HFrEF and inflammation will need to be completed after any accelerated approval is obtained.The key objectives of the meeting are to obtain FDA feedback on relevant chemistry, manufacturing & controls , alignment on potency assays for commercial product release, and Mesoblast’s pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-files-request-type-b-231500036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0149725797.USD","BK4150","MSB.AU","LU1363072403.SGD","BK4139","BK4575","LU0882574139.USD","IE00BHPRN162.USD","LU0267386448.USD","MSC","IE00BZ1G4Q59.USD","BK4006","LU0971096721.USD","MESO","IE00BKVL7J92.USD","IE00B1BXHZ80.USD","MSB","LU0170899867.USD","CMC"],"gpt_icon":0},{"id":"2524417166","title":"Mesoblast (ASX:MSB) Announces Ryoncil Availability But Sees 15% Price Drop Over Past Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2524417166","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524417166?lang=en_us&edition=fundamental","pubTime":"2025-04-03 01:46","pubTimestamp":1743615988,"startTime":"0","endTime":"0","summary":"Mesoblast recently announced the availability of its groundbreaking therapy, Ryoncil, in the United States, yet its share price experienced a 15% decline over the past week. This downturn occurred despite the company's significant progress in healthcare innovation, following its inclusion in the S&P/ASX 200. External factors, like the volatile global market reacting to geopolitical concerns, also contributed to this decline, as broader market indices showed a mixed performance with rising volatility. These market pressures alongside rising uncertainty about new tariffs potentially impacted investor sentiment and influenced Mesoblast's share price performance adversely.View our complete analysis and fair value estimate and you decide.Over the last year, Mesoblast's shares have delivered a striking total return of 111.86%. This performance significantly outperformed both the Australian Biotechs industry, which saw a 7.7% decline, and the broader Australian market, which experienced a 1.7","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-asx-msb-announces-ryoncil-174628204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSB.AU","MESO","BK4006","BK4139","MSB"],"gpt_icon":0},{"id":"2523934123","title":"BRIEF-Mesoblast Says Co Entered Medicaid National Drug Rebate Agreement With US CMS For Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2523934123","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523934123?lang=en_us&edition=fundamental","pubTime":"2025-03-31 09:31","pubTimestamp":1743384673,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Says Co Entered Medicaid National Drug Rebate Agreement With US CMS For RyoncilMarch 31 (Reuters) - Mesoblast Ltd MSB.AX:ENTERED INTO MEDICAID NATIONAL DRUG REBATE AGREEMENT WITH U.S. CMS FOR RYONCILFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC05Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK7067","BK7501","MSB.AU","BK7508","BK4139"],"gpt_icon":0},{"id":"2523939770","title":"Mesoblast Enters Agreement for Ryoncil Treatment Access in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2523939770","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523939770?lang=en_us&edition=fundamental","pubTime":"2025-03-31 09:09","pubTimestamp":1743383352,"startTime":"0","endTime":"0","summary":"Mesoblast  entered an agreement with the US Centers for Medicare & Medicaid Services, enabling access to its US Food and Drug Administration-approved therapy, Ryoncil, according to a Monday filing with the Australian bourse.The agreement ensures coverage for about 40% of US children with steroid-refractory acute graft versus host disease, with mandatory coverage starting July 1, the filing said.The therapy is available to both Medicaid and privately insured children, and the first treatments are set to start this week, the filing added.Shares of the firm fell almost 1% in recent Monday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","BK7501","MESO","MSB.AU","BK4139"],"gpt_icon":0},{"id":"2523802379","title":"First Three Children to Commence Treatment With Ryoncil®","url":"https://stock-news.laohu8.com/highlight/detail?id=2523802379","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523802379?lang=en_us&edition=fundamental","pubTime":"2025-03-31 07:39","pubTimestamp":1743377940,"startTime":"0","endTime":"0","summary":"United States Centers for Medicare and Medicaid Services  Mandates Ryoncil Coverage. NEW YORK, March 30, 2025  -- Mesoblast , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid National Drug Rebate Agreement  with the U.S. Centers for Medicare & Medicaid Services , Department of Health and Human Services, for Ryoncil , the first mesenchymal stromal cell  therapy approved by U.S. Food and Drug Administration  for any indication. The NDRA agreement with Mesoblast means that the U.S. Government now provides inpatient and outpatient access for a treatment course of Ryoncil to the approximately 40% of U.S. children covered by Medicaid who have steroid-refractory acute graft versus host disease , the remainder being covered by private insurance. U.S. states have the option to immediately cover Ryoncil, with mandatory coverage commencing July 1, 2025.Mesoblast is committed to developing additional cell therapies for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/first-three-children-commence-treatment-233900264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","BK4150","BK4139","MESO","MSC","NDRA","MSB","BK4585","LU2346227817.USD","BK4588","LU2500361329.USD","BK4208","LU2637428348.USD","CMS","BK4082","BK4575","LU1894683348.USD","MSB.AU","LU1894683264.USD"],"gpt_icon":0},{"id":"2523875469","title":"Mesoblast Ltd - Entered Into Medicaid National Drug Rebate Agreement With U.S. CMS for Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2523875469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523875469?lang=en_us&edition=fundamental","pubTime":"2025-03-31 07:00","pubTimestamp":1743375618,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250330:nFWN3QC05Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK7508","BK7067","BK7501","MSB.AU","MESO"],"gpt_icon":0},{"id":"2522153743","title":"Thursday’s HotCopper Trends: Mesoblast bags FDA tick, Hot Chili extends mine life | March 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522153743","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522153743?lang=en_us&edition=fundamental","pubTime":"2025-03-27 11:29","pubTimestamp":1743046140,"startTime":"0","endTime":"0","summary":"The ASX has been down 0.55% at 7,956 points on Thursday so far.Energy has been the strongest sector, up 0.75%, followed by Materials, up 0.4%, and Utilities, up 0.25%.Information Technology has been the worst-performing sector, down 2%, followed by Real Estate, down 1.6%, and Discretionary, down 1%.Mesoblast  has been the most watched stock on HotCopper forums today after the company’s proprietary drug Ryoncil scored approval from the U.S. Food and Drug Administration for use in the United States.Also trending on the forums is FBR , which successfully completed an institutional capital raise of $6.3 million at an issue price of one cent per share.Rounding out the most discussed today is Hot Chili  after the miner revealed the life of its Costa Fuego Copper-Gold Project in Chile has been extended to 20 years. The move follows the completion of a Prefeasibility Study.The material provided in this article is for information only and should not be treated as investment advice. Viewers are ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/tuesdays-hotcopper-trends-it-stocks-tank-mesoblast-bags-fda-tick-hit-chili-extend-mine-life-march-27-2025-2025-03-27/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["MESO","BK7077","BK7110","BK7508","BK7501","HCH.AU","MSB.AU","FBR.AU","BK7067","BK4139"],"gpt_icon":0},{"id":"2522391277","title":"Why Domain, Mesoblast, Pro Medicus, and Tuas shares are tumbling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2522391277","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522391277?lang=en_us&edition=fundamental","pubTime":"2025-03-27 10:56","pubTimestamp":1743044164,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is having a poor session on Thursday. In afternoon trade, the benchmark index is down 0.5% to 7,960.9 points. Four ASX shares that are falling more than most today are ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/27/why-domain-mesoblast-pro-medicus-and-tuas-shares-are-tumbling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PME.AU","LU2210150020.SGD","BK4585","BK7503","BK4123","IE0009356076.USD","BK4548","MESO","BK7002","TUA.AU","BK7042","BK7067","MSB.AU","BK7508","XJO.AU","CSGP","DHG.AU","LU0708995401.HKD","BK7501","BK4575","LU0390134368.USD","IE0004445239.USD","BK4150","LU0672654240.SGD","MSC","LU0320765059.SGD","BK4139","LU2210149790.SGD","BK4079","BK7094","BK4588","LU2095319765.USD","LU0109391861.USD","LU1267930730.SGD"],"gpt_icon":0},{"id":"2522365696","title":"Ryoncil® is Now Available for Purchase in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2522365696","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522365696?lang=en_us&edition=fundamental","pubTime":"2025-03-27 08:19","pubTimestamp":1743034740,"startTime":"0","endTime":"0","summary":"NEW YORK, March 26, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil  the first mesenchymal stromal cell  therapy approved by U.S. Food and Drug Administration  for any indication, is now available for purchase in the United States.Ryoncil is approved for treatment of pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease , a condition with high mortality rates. The recommended dosage of Ryoncil for treatment of pediatric SR-aGvHD is 2×106 MSC/kg body weight per intravenous infusion given twice per week for 4 consecutive weeks.To assist patients and institutions with insurance coverage, financial assistance, and access programs, ensuring that no patient is left behind in receiving this potentially life-saving therapy, Mesoblast has established a patient access hub termed MyMesoblast, where Ryoncil is now available for ordering. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ryoncil-now-available-purchase-united-001900042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSB","BK4006","MSB.AU","UBCP","MESO","BK4575","BK4139","BK4150","MSC","BK4211"],"gpt_icon":0},{"id":"2522368087","title":"Mesoblast's Ryoncil Becomes Available for Purchase in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2522368087","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522368087?lang=en_us&edition=fundamental","pubTime":"2025-03-27 07:58","pubTimestamp":1743033514,"startTime":"0","endTime":"0","summary":"Mesoblast's  Ryoncil is now available for purchase in the US, according to a Thursday filing with the Australian bourse.Ryoncil is a US Food and Drug Administration-approved therapy for treating pediatric patients aged two months and above, including adolescents and teenagers, with steroid-refractory acute graft versus host disease or SR-aGvHD, per the filing.Mesoblast's shares were up over 1% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MESO","BK7067","BK7501","MSB.AU","BK7508","BK4139"],"gpt_icon":1},{"id":"2520453608","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2520453608","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520453608?lang=en_us&edition=fundamental","pubTime":"2025-03-20 13:57","pubTimestamp":1742450254,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) enjoyed an enthusiastic rebound today as investors brushed off the worries that dominated the markets yesterday to push decisively higher. By the time the markets clos","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/20/here-are-the-top-10-asx-200-shares-today-20-march-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["AD8.AU","BK7096","BK7501","BK7083","BK7042","BK7067","BK7508","BK7503","PNI.AU","BK7112","NWL.AU","CU6.AU","TPG.AU","CGF.AU","BK7054","XJO.AU","HUB.AU","BOE.AU","BK7073","MSB.AU","BK7062","DYL.AU"],"gpt_icon":1},{"id":"2519894525","title":"Mesoblast Lists Pricing for FDA-Approved Inflammatory Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2519894525","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519894525?lang=en_us&edition=fundamental","pubTime":"2025-03-14 08:32","pubTimestamp":1741912332,"startTime":"0","endTime":"0","summary":"Mesoblast  said that the pricing information for its US Food and Drug Administration  approved inflammatory disease treatment, Ryoncil, is now listed in all four major US drug pricing compendia, according to a Friday filing with the Australian bourse.Ryoncil is the only therapy for pediatric patients aged two months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease, a life-threatening condition with high mortality rates.The listings provide healthcare providers with National Drug Codes , manufacturing details, and uniform pricing for treatment kits, the filing said.Treatment centers can now order kits specific to patient weight with consistent pricing across all categories, the filing added.The pricing compendia include Merative Micromedex RED BOOK, First Databank FDB MedKnowledge, Elsevier Gold Standard Drug Database, and Wolters Kluwer Medi-Span Price Rx.Shares of the company rose 2% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","BK4139","BK7501","MSB.AU","MESO"],"gpt_icon":0},{"id":"2519896007","title":"BUZZ-ASX-listed Mesoblast climbs on Ryoncil pricing information release","url":"https://stock-news.laohu8.com/highlight/detail?id=2519896007","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519896007?lang=en_us&edition=fundamental","pubTime":"2025-03-14 07:55","pubTimestamp":1741910133,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-listed Mesoblast climbs on Ryoncil pricing information release** Shares of ASX-listed Mesoblast MSB.AX rise 2.88% to A$2.14, set for third session of consecutive gains — if trends hold** Stock among the biggest percentage gainers in the ASX200 index .AXJO** Biotech releases pricing information for its product Ryoncil, used to treat a serious condition called graft-versus-host disease, which can happen after a person gets a blood cell transplant** Treatment centres can now order kits tailored to the appropriate dosage for each patient, with pricing applied uniformly, regardless of patient weight — MSB** Pricing details for Ryoncil are now available in all four major drug pricing compendia in the United States** Says that this follows approval and publication by the U.S. Food and Drug Administration of the revised Ryoncil label, which includes revisions to the product prescribing information** Stock down 31.3% YTD including current session  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW1U7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","MSB.AU","BK7501"],"gpt_icon":0},{"id":"2518768995","title":"Investors push Mesoblast (ASX:MSB) 18% lower this week, company's increasing losses might be to blame","url":"https://stock-news.laohu8.com/highlight/detail?id=2518768995","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518768995?lang=en_us&edition=fundamental","pubTime":"2025-03-11 06:41","pubTimestamp":1741646463,"startTime":"0","endTime":"0","summary":"The Mesoblast Limited ( ASX:MSB ) share price is down a rather concerning 34% in the last month. But that doesn't...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/investors-push-mesoblast-asxmsb-18-lower-this-week-companys","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK7067","MESO","BK4211","MSB.AU","BK7501","BK7508","MSB","BK4006","BK4139"],"gpt_icon":1},{"id":"2518789526","title":"Mesoblast Limited (MESO): Among the Best Australian Stocks to Buy According to Billionaires","url":"https://stock-news.laohu8.com/highlight/detail?id=2518789526","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518789526?lang=en_us&edition=fundamental","pubTime":"2025-03-11 05:26","pubTimestamp":1741642007,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Mesoblast Limited  stands against other best Australian stocks to buy according to billionaires.Ausbil expects that Australia’s global interest rate participation will ease in 2025, which is anticipated to support high-quality resource and energy companies. Moreover, the report also expects the earnings growth to recover more than the market anticipates in FY25, broadening across sectors and market capitalization. The FY24 reporting season was weak due to high inflation, higher interest rates, and softness in China. However, looking to 2025, the report foresees relief for balance sheets and income statements from the RBA potentially starting to ease monetary policy, joining other developed markets, which would reduce debt costs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-limited-meso-among-best-212647814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0757428866.USD","BK4137","BK7067","BK4139","MNQmain","USJW.SI","XJO.AU","LU2098885051.SGD","BK7501","LU1815336091.USD","QLD",".IXIC","USAW.SI","RBA","PSQ","XAO.AU","TQQQ","NVIW.SI","XKO.AU","MSB.AU","BK7508","LU1303367103.USD","MESO","TSYW.SI","QID","NQmain","SQQQ"],"gpt_icon":1},{"id":"2517117170","title":"Mesoblast Added to S&P/ASX 200 INDEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2517117170","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517117170?lang=en_us&edition=fundamental","pubTime":"2025-03-07 07:54","pubTimestamp":1741305240,"startTime":"0","endTime":"0","summary":"NEW YORK, March 06, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the S&P Dow Jones Indices’ S&P/ASX 200 Index effective March 6, 2025 on the Australian Stock Exchange .The S&P/ASX 200 is recognized as the institutional investable benchmark in Australia. Index constituents are drawn from eligible companies listed on the ASX. The S&P/ASX 200 is designed to measure the performance of the 200 largest index-eligible stocks listed on the ASX by float-adjusted market capitalization. Representative, liquid, and tradable, it is widely considered Australia’s preeminent benchmark index.About Mesoblast Mesoblast  is a world leader in developing allogeneic  cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory fact","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-added-p-asx-200-235400293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["MSC","BK4150","MESO","BK4139","BK4006","XAO.AU","BK7067","MSB","BK4575","XJO.AU","BK4526","ASX.AU","ASX","BK7508","XKO.AU","BK4141","MSB.AU","BK4543","BK7501","BK7039"],"gpt_icon":0},{"id":"2517740903","title":"BUZZ-Mesoblast tumbles as biotech firm starts trading as part of Australian benchmark index","url":"https://stock-news.laohu8.com/highlight/detail?id=2517740903","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517740903?lang=en_us&edition=fundamental","pubTime":"2025-03-06 10:53","pubTimestamp":1741229639,"startTime":"0","endTime":"0","summary":"BUZZ-Mesoblast tumbles as biotech firm starts trading as part of Australian benchmark index** Shares of biotech firm Mesoblast MSB.AX down 6.5% at A$2.245** MSB falls as much as 7.1% earlier in the day, hitting its lowest since December 18, 2024** First day of trading as a constituent of the S&P/ASX 200 benchmark index .AXJO, which is trading 0.7% lower as of 0223 GMT** Arcadium Lithium ALTM.N, which is being acquired by Rio Tinto RIO.L, RIO.AX, removed from index at start of trading on March 6 ** Melbourne-based MSB, which is developing medicines to treat life-threatening inflammatory conditions, top loser in the benchmark index** MSB's Nasdaq-listed shares MESO.O closed 0.8% higher overnight after a cumulative 14.2% drop in the previous two sessions** MSB reported HY loss of $47.9 million last week, compared with a $32.5 million loss a year earlier** MSB shares down 28% this year, following a 10-fold surge last year  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL6N3PP06E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0612318971.USD","IE0034235071.USD","LU1430597077.USD","LU0345780950.USD","LU0612318385.USD","BK4144","LU0330918003.SGD","LU0171293334.USD","MESO","LU1078025761.USD","SG9999002521.SGD","BK4139","LU0898667661.SGD","RIO.UK","LU0075056555.USD","LU0345781412.USD","LU1023059493.AUD","SG9999001143.SGD","LU1064927863.SGD","LU1130305938.SGD","BK4109","BK7067","IE00BWDBJ516.SGD","BK5111","IE00B3M56506.USD","BK7508","LU0345777147.USD","LU0505663152.USD","LU0630314457.HKD","LU0788109121.HKD","LU0456854461.SGD","MSB.AU","LU0955669360.SGD","LU0654597011.USD","ALTM","LU0266512127.USD","LU0831103253.SGD","BK7501","LU0345777659.USD","LU0011963245.USD","IE00BQJZX424.USD"],"gpt_icon":0},{"id":"2517697113","title":"BRIEF-Mesoblast Added To S&P Asx200 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2517697113","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517697113?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:55","pubTimestamp":1741222527,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Added To S&P Asx200 IndexMarch 6 (Reuters) - Mesoblast MSB.AX:ADDED TO S&P ASX200 INDEX-MSB.AXFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO0W6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK4139","BK7067","BK7501","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2517423971","title":"Why Appen, Mesoblast, Rio Tinto, and Woodside shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2517423971","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517423971?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:54","pubTimestamp":1741222475,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is out of form again on Thursday and sliding into the red. At the time of writing, the benchmark index is down 0.45% to 8,105.4 points. Four ASX shares that are falling","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/06/why-appen-mesoblast-rio-tinto-and-woodside-shares-are-falling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MSB.AU","BK7501","BK7061","BK7142","RIO.AU","APX.AU","MESO","BK7503","BK7508","BK7095","BK4139","BK7511","BK7067","BK7507","XJO.AU","WDS.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":2,"totalSize":166,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[]}}